One-time Total Body Skin Examination May Be Cost-effective

Share this content:
A 1-time total-body skin examination as part of a screening program for the general population may be the most cost-effective strategy.
A 1-time total-body skin examination as part of a screening program for the general population may be the most cost-effective strategy.

A 1-time total-body skin examination (TBSE) as part of a screening program for the general population may be the most cost-effective strategy and reduce skin cancer mortality over 20 and 50 years, according to a study published in JAMA Dermatology.1

Researchers evaluated 1668 cases of TBSE as well as 248 cases of lesion-directed screening (LDS) to determine the cost-effectiveness of these 2 population-based methods. They calculated for cost-effectiveness, which was defined as the societal perspective, and budget effect, which was defined as the public health care payer perspective, through a statistical Markov model that included a latent period of 20 years in addition to a time horizon of 50 years.

The study found that both methods of screening were met with a gain in quality-adjusted life-years (QALYs). Among men, the incremental cost-effectiveness ratio per QALY was €33,072 (equivalent to about $35,475) for TBSE and €34,836 ($37,365) for LDS. Incremental cost-effectiveness ratio per QALY was €18,687 ($20,044) for TBSE and €19,470 ($20,884) for LDS among women.

RELATED: Can White Wine Consumption Lead to Melanoma?

The Markov model found that the 1-time screening resulted in an estimated 4% decrease in the incidence rate of stage 3 or 4 melanoma compared to a screening scenario that didn't have a program. Upon budget effect analysis, the study found that 1-time screening per adult would also produce a net cost of €4.1 ($4.40) for TBSE and €0.7 ($0.80) for LDS.

Both programs also had a “modest” effect on reducing mortality from skin cancer, with a 5.6% reduction with TBSE as well as a 1% reduction with LDS compared to a non-program scenario.

Reference

  1. Pil L, Hoorens I, Vossaert K, et al. Cost-effectiveness and budget effect analysis of a population-based skin cancer screening. JAMA Derm. 2016 Dec 14. doi: 10.1001/jamadermatol.2016.4518 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs